SIE-1

2025-523269-31-00 Protocol ROV-SIE-2025-01 Human pharmacology (Phase I) - Other Authorised, recruiting

Start 2 Jun 2026 · Status Authorised, recruiting · 1 EU/EEA countries · 15 sites · Protocol ROV-SIE-2025-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 120
Countries 1
Sites 15

Hormone receptor-positive early breast cancer in post-menopausal women

Key facts

Sponsor
Laboratorios Farmaceuticos Rovi S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
2 Jun 2026 → ongoing
Decision date (initial)
2026-03-31
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Hormone receptor-positive early breast cancer in post-menopausal women

VersionLevelCodeTermSystem organ class
23.0 PT 10083234 Hormone receptor positive breast cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Laboratorios Farmaceuticos Rovi S.A.

Sponsor organisation
Laboratorios Farmaceuticos Rovi S.A.
Address
Calle De Julian Camarillo 35
City
Madrid
Postcode
28037
Country
Spain

Scientific contact point

Organisation
Laboratorios Farmaceuticos Rovi S.A.
Contact name
Rovi Medical Department

Public contact point

Organisation
Laboratorios Farmaceuticos Rovi S.A.
Contact name
Rovi Medical Department

Locations

1 EU/EEA country · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Authorised, recruiting 57 15
Rest of world
Georgia, United States, Serbia
63

Investigational sites

Spain

15 sites · Authorised, recruiting
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario De Leon
Oncology, Calle Altos De Nava S/n, 24071, Leon
Hospital Universitari General De Catalunya
Oncology, Carrer Pedro I Pons 1, 08195, Sant Cugat Del Valles
Hospital Universitario De Jaen
Oncology, Avenida Del Ejercito Espanol 10, 23007, Jaen
University Clinical Hospital Virgen De La Arrixaca
Oncology, Carretera Madrid-Cartagena S/N, El Palmar, Murcia
Hospital Universitario Fundacion Alcorcon
Oncology, Calle Budapest 1, 28922, Alcorcon
Institut Catala D'oncologia
Oncology, Avinguda De Franca S/n, 17007, Girona
Salut Sant Joan De Reus
Oncology, Avinguda Del Doctor Josep Laporte 2, 43204, Reus
Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada
Oncology, Carrer Del Doctor Joan Soler 1-3, 08243, Manresa
Complexo Hospitalario Universitario De Santiago
Oncology, Calle Choupana Da S/n, 15706, Santiago De Compostela
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario Virgen De Las Nieves
Oncology, Avenida De Las Fuerzas Armadas 2, 18014, Granada
Parc Tauli Hospital Universitari
Oncology, Parc Del Tauli 1, 08208, Sabadell
Hospital Quironsalud Malaga
Oncology, Avenida Imperio Argentina 1, 29004, Malaga
Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida
Oncology, Avinguda De L'alcalde Rovira Roure 80, 25196, Lleida

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2026-06-02

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-12-12 Spain Acceptable
2026-03-23
2026-03-31
2 SUBSTANTIAL MODIFICATION SM-1 2026-04-23 Spain Acceptable 2026-05-19